Details of Disease

General Information of Disease (ID: DISYZHCP)

• Disease Name: Large cell lymphoma
• Synonyms: sarcoma of reticular cell; reticulum cell sarcoma; reticular cell sarcoma; reticulosarcoma; histiocytic lymphoma; large-cell Lymphomas; interdigitating cell sarcoma; Reticulum cell sarcoma
• Disease Class: 2A80: Follicular lymphoma
• Definition: An antiquated term that refers to a non-Hodgkin lymphoma composed of diffuse infiltrates of large, often anaplastic lymphocytes.|Editor note: check this
• Disease Hierarchy:
  DISUX76L: Lymphatic system cancer
  DISG6V5T: Dendritic cell tumor
  DISZDG3U: Sarcoma
  DISYZHCP: Large cell lymphoma
• ICD Code: ICD-11: ICD-11: 2A80.Z
• Disease Identifiers:
  MONDO ID: MONDO_0009975
  MESH ID: D008228
  UMLS CUI: C0024302
  OMIM ID: 267730
  MedGen ID: 44224
  Orphanet ID: 86900
  SNOMED CT ID: 189982000

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CD19 CAR T Cells	DMUARWH	Phase 1/2	CAR T Cell Therapy	[1]
CD20-Specific CAR T Cells	DMHPZ8G	Phase 1/2	CAR T Cell Therapy	[2]
Anti-CD19-CAR	DMWKYSM	Phase 1	CAR T Cell Therapy	[3]
Anti-CD30-CAR T cells	DM2IEB7	Phase 1	CAR T Cell Therapy	[4]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 15 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
TFRC	TT8MG4S	Limited	Biomarker	[5]
BCL6	TTC9YX5	Disputed	Biomarker	[6]
GUCY2D	TTWNFC2	moderate	Biomarker	[7]
TYMS	TTP1UKZ	moderate	Biomarker	[8]
CBS	TTVZJ7G	Strong	Biomarker	[9]
CHEK2	TT9ABMF	Strong	Biomarker	[10]
CSF2	TTNYZG2	Strong	Therapeutic	[11]
CYP2E1	TTWVHQ5	Strong	Biomarker	[12]
HLA-DRB1	TTUXSTW	Strong	Biomarker	[13]
HNMT	TT2B6EV	Strong	Biomarker	[14]
IFNA2	TTSIUJ9	Strong	Therapeutic	[15]
MTHFR	TTQWOU1	Strong	Biomarker	[16]
RNASEL	TT7V0K4	Strong	Biomarker	[17]
TNFRSF8	TT2GM5R	Strong	Biomarker	[18]
CSF3	TT5TQ2W	Definitive	Therapeutic	[19]

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC35B2	DT81RKJ	moderate	Biomarker	[20]

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
EPHX1	DELB4KP	Strong	Biomarker	[12]
FPGS	DECWT2V	Strong	Biomarker	[9]

This Disease Is Related to 12 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CLTA	OTLHOXMQ	moderate	Biomarker	[7]
BHMT	OTYB6PXZ	Strong	Biomarker	[9]
CCT4	OT5D452X	Strong	Biomarker	[14]
GUCA1B	OT85S0J3	Strong	Biomarker	[21]
LMNB1	OT100T3P	Strong	Biomarker	[22]
NRSN1	OT1KKXC8	Strong	Altered Expression	[23]
PDLIM7	OTAZVODU	Strong	Altered Expression	[24]
RFXANK	OTDX1026	Strong	Genetic Variation	[25]
SCAPER	OT7S3B3P	Strong	Biomarker	[26]
SHMT1	OTIINA3J	Strong	Biomarker	[9]
SIRPB1	OTGHALWJ	Strong	Biomarker	[26]
TMED2	OTBLO7RW	Strong	Altered Expression	[23]

References

• [1] ClinicalTrials.gov (NCT01475058) CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant
• [2] ClinicalTrials.gov (NCT03277729) A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
• [3] ClinicalTrials.gov (NCT01593696) Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
• [4] ClinicalTrials.gov (NCT03049449) T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
• [5] The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer.Clin Immunol. 2006 Nov;121(2):144-58. doi: 10.1016/j.clim.2006.06.010. Epub 2006 Aug 10.
• [6] Suppression of human B cell activation by 2,3,7,8-tetrachlorodibenzo-p-dioxin involves altered regulation of B cell lymphoma-6.Toxicol Sci. 2015 Mar;144(1):39-50. doi: 10.1093/toxsci/kfu257. Epub 2014 Dec 26.
• [7] Relationship between Epstein-Barr virus and lymphoepithelioma-like carcinoma of the lung: a clinicopathologic study of 6 cases and review of the literature.Hum Pathol. 2001 Aug;32(8):863-72. doi: 10.1053/hupa.2001.26457.
• [8] Risk of non-Hodgkin lymphoma associated with polymorphisms in folate-metabolizing genes.Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2999-3003. doi: 10.1158/1055-9965.EPI-05-0515.
• [9] Gene-nutrient interactions among determinants of folate and one-carbon metabolism on the risk of non-Hodgkin lymphoma: NCI-SEER case-control study.Blood. 2007 Apr 1;109(7):3050-9. doi: 10.1182/blood-2006-07-034330.
• [10] Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin Lymphoma.PLoS One. 2015 Oct 27;10(10):e0140819. doi: 10.1371/journal.pone.0140819. eCollection 2015.
• [11] DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).Eur J Haematol Suppl. 2001 Jul;64:41-5.
• [12] Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin's and non-Hodgkin's lymphomas.Hum Mol Genet. 2001 Jun 1;10(12):1265-73. doi: 10.1093/hmg/10.12.1265.
• [13] Variation in effects of non-Hodgkin lymphoma risk factors according to the human leukocyte antigen (HLA)-DRB1*01:01 allele and ancestral haplotype 8.1.PLoS One. 2011;6(11):e26949. doi: 10.1371/journal.pone.0026949. Epub 2011 Nov 9.
• [14] Repositioning of Difluorinated Propanediones as Inhibitors of Histone Methyltransferases and their Biological Evaluation in Human Leukemic Cell Lines.Anticancer Agents Med Chem. 2018;18(13):1892-1899. doi: 10.2174/1871520618666180404125721.
• [15] Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement.Ann Oncol. 1994;5 Suppl 2:73-7. doi: 10.1093/annonc/5.suppl_2.s73.
• [16] Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival. Haematologica. 2007 Apr;92(4):478-85. doi: 10.3324/haematol.10587.
• [17] Mapping of the human RNASEL promoter and expression in cancer and normal cells.J Interferon Cytokine Res. 2005 Oct;25(10):595-603. doi: 10.1089/jir.2005.25.595.
• [18] Cutaneous anaplastic large cell lymphoma in a multiple sclerosis patient receiving Fingolimod.Mult Scler Relat Disord. 2018 Jan;19:121-123. doi: 10.1016/j.msard.2017.11.012. Epub 2017 Nov 22.
• [19] High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150.Leuk Lymphoma. 2001 Nov-Dec;42(6):1255-64. doi: 10.3109/10428190109097750.
• [20] Transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma to interdigitating dendritic cell sarcoma: evidence for transdifferentiation of the lymphoma clone.Am J Clin Pathol. 2009 Dec;132(6):928-39. doi: 10.1309/AJCPWQ0I0DGXBMHO.
• [21] Induction of leukemia cell differentiation and apoptosis by recombinant P48, a modulin derived from Mycoplasma fermentans.Biochem Biophys Res Commun. 2000 Mar 5;269(1):284-9. doi: 10.1006/bbrc.2000.2282.
• [22] Mechanisms of JP-8 jet fuel toxicity. I. Induction of apoptosis in rat lung epithelial cells.Toxicol Appl Pharmacol. 2001 Mar 1;171(2):94-106. doi: 10.1006/taap.2000.9108.
• [23] Identification of a common clonal human immunodeficiency virus integration site in human immunodeficiency virus-associated lymphomas.Cancer Res. 1994 Apr 15;54(8):2069-72.
• [24] AIDS-related non-Hodgkin's lymphomas: from pathology and molecular pathogenesis to treatment.Hum Pathol. 2002 Apr;33(4):392-404. doi: 10.1053/hupa.2002.124723.
• [25] Large B cell lymphoma presenting initially in bone marrow, liver and spleen: an aggressive entity associated frequently with haemophagocytic syndrome.Histopathology. 2010 Dec;57(6):785-95. doi: 10.1111/j.1365-2559.2010.03709.x.
• [26] High-resolution genomic profiling reveals clonal evolution and competition in gastrointestinal marginal zone B-cell lymphoma and its large cell variant.Int J Cancer. 2013 Feb 1;132(3):E116-27. doi: 10.1002/ijc.27774. Epub 2012 Sep 1.